TP53 and breast cancer: Although in normal cells doxorubicin and ATM converge on the activation of p53 [58], we here observed that, in the breast cancer cells used in this study, the impact of mitochondrial targeting, ATM inhibition, and the suppression of doxorubicin resistance were independent of the p53 status of the cells (Figure 5).